Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

NCT00184015 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT00184015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00184015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 18, 2005
Completion date
August 21, 2018
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell cancer